10x Genomics, Inc. TXG Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s cash & equivalents?
- 10x Genomics, Inc. (TXG) reported cash & equivalents of $490.29M in Q1 2026.
- How has 10x Genomics, Inc.'s cash & equivalents changed year-over-year?
- 10x Genomics, Inc.'s cash & equivalents increased by 30.0% year-over-year, from $377.06M to $490.29M.
- What is the long-term trend for 10x Genomics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s cash & equivalents has grown at a -7.2% compound annual growth rate (CAGR), from $688.64M to $473.97M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.